menu
    • menu
    [{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TMB-607","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiMed Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiMed Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Westat","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Westat","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ Westat"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Aaron Diamond AIDS Research Center | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TaiMed Biologics \/ Aaron Diamond AIDS Research Center | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ Aaron Diamond AIDS Research Center | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TaiMed Biologics \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ AcedrA BioPharmaceuticals"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiMed Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Westat","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiMed Biologics \/ Westat","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ Westat"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TMB-365","moa":"||T-cell surface glycoprotein CD4 (CD4)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiMed Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TMB-365","moa":"T-cell surface glycoprotein CD4 (CD4)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiMed Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiMed Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Westat","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TMB-365","moa":"T-cell surface glycoprotein CD4 (CD4)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiMed Biologics \/ Westat","highestDevelopmentStatusID":"8","companyTruncated":"TaiMed Biologics \/ Westat"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TMB-365","moa":"T-cell surface glycoprotein CD4 (CD4)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TaiMed Biologics \/ Undisclosed"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Kaiser Permanente","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Kaiser Permanente","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ Kaiser Permanente"}]

    Find Clinical Drug Pipeline Developments & Deals by TaiMed Biologics

    Menu

    TaiMed Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

                            Details : TMB-365 is a large molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2025

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : AcedrA BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiMed Partners with AcedrA To Commercialize Trogarzo® in MENA Region

                            Details : AcedrA will register, promote, and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor, for treating HIV-1 infection in the MENA region.

                            Product Name : Trogarzo

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 18, 2024

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : AcedrA BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365,TMB-380

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment

                            Details : TMB-365/380 monoclonal antibodies is an ultra-long-acting new drug combination, which is investigated for the treatment of human immunodeficiency virus infection.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2023

                            Lead Product(s) : TMB-365,TMB-380

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

                            Details : TMB-365 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

                            Details : TMB-365 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2019

                            Lead Product(s) : TMB-365

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety of Trogarzoâ„¢ Administered as an Undiluted "IV Push" or an Intramuscular Injection

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 12, 2019

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TMB-607

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

                            Details : TMB-607 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2017

                            Lead Product(s) : TMB-607

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 14, 2016

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Westat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 19, 2015

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TaiMed Biologics

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Aaron Diamond AIDS Research Center | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

                            Details : Ibalizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 09, 2011

                            Lead Product(s) : Ibalizumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Aaron Diamond AIDS Research Center | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth